June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Development of sd-rxRNA® for Retinoblastoma Therapy
Author Affiliations & Notes
  • Michael Byrne
    Pharmacology, RXi Pharmaceuticals, Westborough, MA
  • Hardeep Singh
    Memorial Sloan-Kettering Cancer Center, New York, NY
  • Donglai Qi
    Memorial Sloan-Kettering Cancer Center, New York, NY
  • James Cardia
    Pharmacology, RXi Pharmaceuticals, Westborough, MA
  • Lakshmipathi Pandarinathan
    Pharmacology, RXi Pharmaceuticals, Westborough, MA
  • Katherine Holton
    Pharmacology, RXi Pharmaceuticals, Westborough, MA
  • Karen Bulock
    Pharmacology, RXi Pharmaceuticals, Westborough, MA
  • Lyn Libertine
    Pharmacology, RXi Pharmaceuticals, Westborough, MA
  • David Cobrinik
    Memorial Sloan-Kettering Cancer Center, New York, NY
  • Pamela Pavco
    Pharmacology, RXi Pharmaceuticals, Westborough, MA
  • Footnotes
    Commercial Relationships Michael Byrne, RXi Pharmaceuticals (E); Hardeep Singh, None; Donglai Qi, None; James Cardia, RXi Pharmaceuticals (E); Lakshmipathi Pandarinathan, RXi Pharmaceuticals (E); Katherine Holton, RXi Pharmaceuticals (E); Karen Bulock, RXi Pharmaceuticals (E), RXi Pharmaceuticals (P); Lyn Libertine, RXi Pharmaceuticals (E); David Cobrinik, None; Pamela Pavco, RXi Pharmaceuticals Corp. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1258. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Byrne, Hardeep Singh, Donglai Qi, James Cardia, Lakshmipathi Pandarinathan, Katherine Holton, Karen Bulock, Lyn Libertine, David Cobrinik, Pamela Pavco; Development of sd-rxRNA® for Retinoblastoma Therapy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1258.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Retinoblastoma is a cancer that originates in the retina and primarily affects young children. It is driven by RB mutations as well as the expression of genes involved in the “normal” signaling circuitry of retinal cells, particularly that of cone precursors. Some of these genes have been found to be critical to retinoblastoma cell growth and survival, suggesting that they may be effective therapeutic targets. We have developed a new class of stable, self-delivering RNAi compounds (sd-rxRNA®) that incorporate features of RNAi and antisense and results in spontaneous cellular uptake. Our goal is to use the sd-rxRNA platform to develop compounds against novel retinoblastoma therapeutic targets. Earlier studies of control sd-rxRNAs in the eye resulted in spontaneous cellular uptake in the retina as well as statistically significant reduction of target mRNA levels for up to 21 days. To determine the potential of using sd-rxRNAs to target genes involved in retinoblastoma, we examined in vitro mRNA silencing in retinoblastoma cell lines as well as in vivo uptake by human retinoblastoma cells in a mouse model.

Methods: For in vitro studies, retinoblastoma cell lines RB176, RB177 and Y79 were treated with sd-rxRNA targeting the PPIB gene for 48 hours, after which PPIB mRNA levels were analyzed by qPCR. For in vivo studies, 10 ug of DY547- labeled sd-rxRNA was administered by intravitreal injection to mouse eyes that were seeded subretinally 3 weeks earlier with Y79 cells.

Results: In all retinoblastoma cell lines tested, PPIB was silenced in a dose-dependent manner at 48 hours post administration relative to a non-targeting control sd-rxRNA. Twenty-four hours post intravitreal injection in mouse eyes, sd-rxRNA was visible in tumor cells in the subretinal space and in the vitreous.

Conclusions: sd-rxRNAs reduce targeted mRNA levels in retinoblastoma cell lines. Additionally, sd-rxRNA is delivered to all cell layers of the retina and is taken up by tumor cells within 24 hours of intravitreal administration. These findings, along with our previous report of specific and extended silencing of retinal genes by sd-rxRNA, support the potential use of an sd-rxRNA treatment for retinoblastoma. Our next step is to design and characterize sd-rxRNA compounds against novel retinoblastoma targets and to evaluate their ability to reduce target mRNA levels in human retinoblastoma cells in vivo using an orthotopic mouse xenograft model.

Keywords: 703 retinoblastoma • 533 gene/expression  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×